Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NEPH 
Nephros Inc (NEPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/10/2025: NEPH (3-star) is a WEAK-BUY. BUY since 42 days. Simulated Profits (0.70%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 96.41% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.76M USD | Price to earnings Ratio 38.33 | 1Y Target Price 6.5 |
Price to earnings Ratio 38.33 | 1Y Target Price 6.5 | ||
Volume (30-day avg) 2 | Beta 1.47 | 52 Weeks Range 1.39 - 5.98 | Updated Date 11/10/2025 |
52 Weeks Range 1.39 - 5.98 | Updated Date 11/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.015 | Actual 0.03 |
Profitability
Profit Margin 8.26% | Operating Margin (TTM) 6.59% |
Management Effectiveness
Return on Assets (TTM) 7.64% | Return on Equity (TTM) 16.29% |
Valuation
Trailing PE 38.33 | Forward PE - | Enterprise Value 45353802 | Price to Sales(TTM) 2.72 |
Enterprise Value 45353802 | Price to Sales(TTM) 2.72 | ||
Enterprise Value to Revenue 2.72 | Enterprise Value to EBITDA 30.36 | Shares Outstanding 10600604 | Shares Floating 9266574 |
Shares Outstanding 10600604 | Shares Floating 9266574 | ||
Percent Insiders 11.17 | Percent Institutions 45.27 |
Upturn AI SWOT
Nephros Inc
Company Overview
History and Background
Nephros, Inc. was founded in 1997 and is a commercial stage medical device company focused on developing and commercializing high performance liquid purification and pathogen detection technologies. Initially focused on dialysis, they expanded to include filtration products for infection control.
Core Business Areas
- Medical Devices: Development and commercialization of ultrafilters and related products used in hemodialysis and hemofiltration.
- Water Purification: Development and sale of water filtration systems for hospitals and other healthcare facilities to prevent waterborne infections.
Leadership and Structure
Nephros has a CEO and a management team overseeing its various departments including R&D, sales, and marketing. The company operates with a board of directors responsible for strategic oversight.
Top Products and Market Share
Key Offerings
- Hemodialysis Ultrafilters: High-flux dialyzers used in hemodialysis treatments. Market share is relatively small, facing competition from larger dialysis companies such as DaVita (DVA) and Fresenius Medical Care (FMS). Data on precise market share is not publicly available. Competitors: DaVita (DVA), Fresenius Medical Care (FMS), Baxter International (BAX).
- AAMI-Grade Water Filtration Systems: Water filtration systems designed to meet AAMI standards for water quality in healthcare settings. Competitors: Pall Corporation (acquired by Danaher DHR), Mar Cor Purification (Cantel Medical, now Steris STE).
Market Dynamics
Industry Overview
The medical device and water purification industries are competitive, with demand driven by factors such as aging populations, increased prevalence of kidney disease, and growing awareness of healthcare-associated infections.
Positioning
Nephros occupies a niche market within the broader dialysis and water purification sectors, focusing on specialized high-performance filters. Their competitive advantage lies in their proprietary filtration technology.
Total Addressable Market (TAM)
The global dialysis market is valued at billions of dollars annually. Water purification systems for healthcare are also a significant market. Nephros is positioned to capture a portion of this TAM by focusing on high-performance, niche applications.
Upturn SWOT Analysis
Strengths
- Proprietary filtration technology
- Focus on niche markets with high-performance demands
- Experienced management team
Weaknesses
- Limited financial resources compared to larger competitors
- Concentrated product portfolio
- Dependence on regulatory approvals
Opportunities
- Expanding into new geographic markets
- Developing new applications for their filtration technology
- Strategic partnerships and acquisitions
Threats
- Intense competition from larger companies
- Changing regulatory landscape
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- DVA
- FMS
- BAX
- DHR
- STE
Competitive Landscape
Nephros faces significant competition from larger, more established companies. To be competitive, they focus on niche products and customer service.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been uneven, reflecting the challenges of a small company in a competitive market.
Future Projections: Future growth depends on successful product launches, market penetration, and strategic execution. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expansion of product lines and focus on high growth areas.
Summary
Nephros is a small medical device company with a focus on filtration technology. Its strengths lie in its proprietary technology and focus on niche markets. The company faces challenges related to competition from larger players and the need for regulatory approvals. Future success depends on successful product launches and strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nephros Inc
Exchange NASDAQ | Headquaters South Orange, NJ, United States | ||
IPO Launch date 2004-09-21 | President, CEO & Director Mr. Robert Banks | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 31 | Website https://www.nephros.com |
Full time employees 31 | Website https://www.nephros.com | ||
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, bacteria, cysts, particulates, heavy metals, chemical compounds, scale build-up in downstream equipment, and other various contaminants. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.